Manning Paul B

Average Profitability
<0.0001%
Insider Buys Quantity
34
Insider Buys Sum
$84.39M
Insider Sells Quantity
0
Insider Sells Sum
$0

Insider Activity of Manning Paul B

According to the SEC Form 4 filings, Manning Paul B, being in a position of

  1. director at Liquidia Corporation,
    оver the last 12 months, has bought 616408 shares for $5M, and sold 0 shares,
    over all time since 2021-04-13, has bought 1405390 shares for $8M, and sold 0 shares.

The largest purchase of all time was on 2023-08-16 and amounted to 16466667 shares of Taysha Gene Therapies, Inc. for $14.82M.

Biography of Manning Paul B

No biography is available at this moment.

2024-09-12PurchaseLiquidia Corporation
LQDA
director
337,078
0.4019%
$8.90$3M+9.93%
2024-06-27PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
1.33M
0.7863%
$2.25$3M0%
2023-12-14PurchaseLiquidia Corporation
LQDA
director
279,330
0.4244%
$7.16$2M+71.76%
2023-11-17PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
100,000
0.0519%
$1.63$163,000+28.74%
2023-08-16PurchaseTaysha Gene Therapies, Inc.
TSHA
10 percent owner
16.47M
11.9647%
$0.90$14.82M+21.5%
2023-07-24PurchaseVerrica Pharmaceuticals Inc.
VRCA
200,000
0.4567%
$5.02$1M+4.11%
2022-10-31PurchaseTaysha Gene Therapies, Inc.
TSHA
director
1.5M
3.9684%
$2.00$3M-34.88%
2022-07-05PurchaseVerrica Pharmaceuticals Inc.
VRCA
4.76M
9.9243%
$2.10$10M+61.6%
2022-04-18PurchaseLiquidia Corporation
LQDA
392,156
0.6258%
$5.10$2M+9.53%
2022-02-03PurchaseTaysha Gene Therapies, Inc.
TSHA
76,602
0.2022%
$7.84$600,560-59%
2022-02-02PurchaseTaysha Gene Therapies, Inc.
TSHA
125,000
0.3321%
$7.77$971,250-57.83%
2021-12-03PurchaseVerrica Pharmaceuticals Inc.
VRCA
19,977
0.0723%
$9.22$184,188-57.78%
2021-12-02PurchaseVerrica Pharmaceuticals Inc.
VRCA
30,023
0.1097%
$9.45$283,717-58.35%
2021-11-24PurchaseTaysha Gene Therapies, Inc.
TSHA
2,202
0.0057%
$13.19$29,044-68.09%
2021-11-23PurchaseTaysha Gene Therapies, Inc.
TSHA
20,000
0.0513%
$12.54$250,800-66.71%
2021-07-29PurchaseCandel Therapeutics, Inc.
CADL
1.63M
7.6346%
$8.00$13M-24.18%
2021-07-27PurchaseCandel Therapeutics, Inc.
CADL
director
36,000
0.1622%
$7.36$264,834-18.36%
2021-07-06PurchaseAcumen Pharmaceuticals, Inc.
ABOS
10 percent owner
312,500
0.6468%
$16.00$5M-67.95%
2021-05-14PurchaseTaysha Gene Therapies, Inc.
TSHA
12,000
0.0321%
$20.98$251,760-28.44%
2021-04-13PurchaseLiquidia Corporation
LQDA
396,826
0.7682%
$2.52$1M+23.24%
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.